The latest indication of regorafenib for liver cancer comes from the RESORCE clinical study, a large, randomized, double Blind, placebo-controlled clinical study involving 527 adults with HCC who progressed after treatment with sorafenib. In this report, we’ll take a look at what happened and what the overall conclusion is.
The study enrolled patients aged 65 years and above who had at least one episode of cirrhosis (liver cancer) in the previous five years. All patients completed a four-week course of sorafenib. Within this group, those who responded to the regorafenib like Acalabrutinib
（ACP-196）had a significant improvement in both the frequency and magnitude of their symptoms and had a statistically significant change in the percentage of liver cells that were cancerous. Although the percentages of response for the placebo and control groups were similar, the difference in the survival rates was quite noteworthy.
The investigators looked for differences between the placebo and treatment groups. They specifically wanted to evaluate whether the addition of a chemotherapeutic agent, such as regorafenib, was associated with an increased risk of death or an increased risk of progression of liver cancer.
Because the study was observational, there were no data to indicate whether the addition of the drug was actually responsible for these changes, only that the patients who received sorafenib through the
regorafenib at
https://www.aasraw.com/products/regorafenib/ group had a statistically significant improvement in symptoms.
However, the investigators did note that all patients in the treatment group but one were diagnosed with liver cancer. While the majority of patients in the placebo arm did not develop liver cancer, those in the treatment arm had a higher than normal risk of progression to a more severe form of liver cancer.
Patients may feel better but should realize that the benefits are not permanent. Because the effects of sorafenib are most apparent when compared to other treatments for liver cancer, patients should also understand that treatment with the aforementioned drug is not a cure for this condition.
In fact, the success of regorafenib may depend on how long the patient lives after completing the course of treatment. If you plan to undergo treatment for this condition, speak to your physician about what the possible side effects are. You should also inform your doctor about any medications you’re taking, especially over-the-counter drugs.
Regorafenib is used in the treatment of liver cancer, liver cirrhosis and hepatocellular carcinoma. As with any medication, the side effects and complications from using regorafenib can range from mild to severe. Common side effects include nausea, vomiting, diarrhea and fever. If these symptoms occur, speak to your doctor immediately and advise him or her of the best course of treatment. In extreme cases, life-threatening side effects can occur.
Regorafenib has been found to be highly effective in the treatment of malignant liver cancer in both pre-cancer and post-treatment stages. For this reason, it’s been shown to improve survival and prolong life for those who have cancerous livers. However, before you decide whether or not to take regorafenib for livers cancer, talk to your doctor.
He or she will be able to give you the safest and most effective treatment possible for your cancer. In the meatime, try taking part in one of the many different alternative therapies available to help manage symptoms and the disease as well.
